Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair

NCT06898450 is registered in ClinicalTrials.gov with Nimbus Wadjet, Inc. as lead sponsor.

NCT NCT06898450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06898450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
Lead sponsor
Nimbus Wadjet, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2025
Completion date
December 31, 2031
Enrollment
134 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors cancer, msi-h cancer